desmopressin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasopressin analogues 817 16679-58-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desmopressin acetate hydrate
  • minirinmelt
  • desmopressin
  • adiuretin
  • minirin
  • desmopressin acetate
  • DDAVP
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
  • Molecular weight: 1069.22
  • Formula: C46H64N14O12S2
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 26
  • HDO: 14
  • TPSA: 435.41
  • ALOGS: -3.99
  • ROTB: 19

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mcg N
0.40 mg O
4 mcg P
0.24 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 47 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.10 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Feb. 21, 1978 FDA FERRING PHARMS INC
June 18, 2019 PMDA FERRING PHARMACEUTICALS CO., LTD.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 576.62 18.04 252 5417 111648 63371705
Hyponatraemic encephalopathy 178.32 18.04 29 5640 227 63483126
Hyponatraemic seizure 110.84 18.04 21 5648 422 63482931
Craniopharyngioma 110.77 18.04 18 5651 140 63483213
Recalled product administered 107.29 18.04 21 5648 504 63482849
Hypernatraemia 84.39 18.04 30 5639 7579 63475774
Seizure 81.26 18.04 78 5591 132556 63350797
Water intoxication 80.69 18.04 16 5653 411 63482942
Poor quality product administered 69.85 18.04 21 5648 3135 63480218
Diabetes insipidus 69.20 18.04 20 5649 2605 63480748
Blood sodium decreased 61.88 18.04 34 5635 24218 63459135
Renal salt-wasting syndrome 59.73 18.04 12 5657 330 63483023
Pharyngeal haemorrhage 59.08 18.04 13 5656 559 63482794
Adrenocortical insufficiency acute 54.09 18.04 15 5654 1683 63481670
Tonsillar disorder 50.02 18.04 13 5656 1140 63482213
Brain injury 49.85 18.04 20 5649 7023 63476330
Patent ductus arteriosus 48.04 18.04 17 5652 4233 63479120
Electrolyte imbalance 45.38 18.04 26 5643 20050 63463303
Osmotic demyelination syndrome 41.36 18.04 10 5659 653 63482700
Product prescribing error 41.35 18.04 27 5642 26262 63457091
Oesophageal disorder 36.66 18.04 12 5657 2361 63480992
Brain oedema 36.47 18.04 20 5649 14175 63469178
Premature baby 34.34 18.04 22 5647 20713 63462640
Blood sodium increased 31.15 18.04 11 5658 2721 63480632
Labelled drug-disease interaction medication error 30.65 18.04 6 5663 144 63483209
Insulin-like growth factor decreased 30.06 18.04 7 5662 389 63482964
Hepatitis toxic 29.28 18.04 11 5658 3242 63480111
Hypoosmolar state 29.17 18.04 6 5663 186 63483167
Oligohydramnios 28.27 18.04 13 5656 6353 63477000
Polyuria 27.52 18.04 14 5655 8528 63474825
Hypopituitarism 26.97 18.04 8 5661 1140 63482213
Exposure during pregnancy 26.77 18.04 49 5620 155498 63327855
Gastrointestinal infection 26.42 18.04 14 5655 9267 63474086
Thoracotomy 25.66 18.04 4 5665 23 63483330
Abortion induced 25.13 18.04 14 5655 10228 63473125
Headache 24.95 18.04 117 5552 633124 62850229
Neoplasm recurrence 24.03 18.04 9 5660 2629 63480724
Foetal exposure during pregnancy 23.80 18.04 21 5648 31941 63451412
Cutaneous lupus erythematosus 23.79 18.04 9 5660 2703 63480650
Generalised tonic-clonic seizure 23.49 18.04 20 5649 28996 63454357
Encephalopathy 22.25 18.04 22 5647 38598 63444755
Germ cell cancer 21.80 18.04 4 5665 67 63483286
Blood sodium abnormal 21.31 18.04 6 5663 711 63482642
Urine output decreased 21.18 18.04 13 5656 11357 63471996
Hypothalamo-pituitary disorder 21.02 18.04 6 5663 747 63482606
Urine sodium increased 20.24 18.04 4 5665 101 63483252
Insulin-like growth factor increased 19.84 18.04 6 5663 913 63482440
Disseminated intravascular coagulation 19.37 18.04 15 5654 19036 63464317
Pituitary tumour benign 18.88 18.04 7 5662 1988 63481365
Hypoglycaemia 18.88 18.04 25 5644 60040 63423313
Thirst 18.67 18.04 13 5656 14028 63469325
Epilepsy 18.60 18.04 17 5652 27048 63456305

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 406.83 16.89 219 5533 82472 34868707
Craniopharyngioma 149.75 16.89 28 5724 271 34950908
Water intoxication 93.08 16.89 20 5732 408 34950771
Chorioretinopathy 72.70 16.89 21 5731 1472 34949707
Diabetes insipidus 70.33 16.89 24 5728 2904 34948275
Osmotic demyelination syndrome 69.50 16.89 18 5734 837 34950342
Head titubation 66.11 16.89 15 5737 396 34950783
Hypernatraemia 60.42 16.89 29 5723 8461 34942718
Hyponatraemic encephalopathy 58.74 16.89 10 5742 53 34951126
Labelled drug-disease interaction medication error 51.43 16.89 10 5742 121 34951058
Seizure 49.82 16.89 73 5679 104784 34846395
Cogwheel rigidity 48.41 16.89 15 5737 1337 34949842
Germ cell cancer 40.61 16.89 8 5744 104 34951075
Apnoeic attack 39.68 16.89 10 5742 416 34950763
Extrapyramidal disorder 38.86 16.89 25 5727 12855 34938324
Renal salt-wasting syndrome 36.66 16.89 9 5743 336 34950843
Sedation complication 36.64 16.89 13 5739 1764 34949415
Inappropriate antidiuretic hormone secretion 36.63 16.89 24 5728 12729 34938450
Neoplasm recurrence 33.65 16.89 13 5739 2236 34948943
Hypopituitarism 33.47 16.89 13 5739 2269 34948910
Serotonin syndrome 33.25 16.89 27 5725 19906 34931273
Polyuria 31.84 16.89 19 5733 8555 34942624
Duplicate therapy error 31.25 16.89 7 5745 174 34951005
Epiphysiolysis 29.01 16.89 6 5746 101 34951078
Reaction to excipient 28.47 16.89 8 5744 507 34950672
Insulin-like growth factor decreased 28.39 16.89 7 5745 266 34950913
Recalled product administered 28.08 16.89 8 5744 533 34950646
Hyperadrenocorticism 27.89 16.89 6 5746 123 34951056
Rebound effect 25.79 16.89 12 5740 3262 34947917
Pharyngeal haemorrhage 25.33 16.89 8 5744 759 34950420
Blood sodium increased 24.19 16.89 11 5741 2837 34948342
Urinary tract infection 23.19 16.89 46 5706 84035 34867144
Urine osmolarity increased 22.18 16.89 5 5747 128 34951051
Flushing 22.16 16.89 27 5725 32393 34918786
Insulin-like growth factor increased 21.54 16.89 8 5744 1235 34949944
Pollakiuria 21.53 16.89 21 5731 19653 34931526
Anticholinergic syndrome 21.38 16.89 8 5744 1261 34949918
Compulsive shopping 21.09 16.89 6 5746 398 34950781
Implant site pruritus 21.06 16.89 3 5749 3 34951176
CNS germinoma 21.06 16.89 3 5749 3 34951176
Polydipsia 20.87 16.89 11 5741 3904 34947275
Toxic neuropathy 19.16 16.89 6 5746 553 34950626
Urinary retention 18.26 16.89 26 5726 36262 34914917
Akathisia 17.94 16.89 13 5739 8096 34943083
Therapeutic response decreased 17.78 16.89 23 5729 29290 34921889
Hyperthermia malignant 17.21 16.89 8 5744 2169 34949010
Muscle rigidity 17.01 16.89 14 5738 10504 34940675
Product use in unapproved indication 16.92 16.89 50 5702 117449 34833730

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 891.95 15.02 432 9268 177416 79557272
Hyponatraemic encephalopathy 214.58 15.02 37 9663 303 79734385
Craniopharyngioma 195.35 15.02 35 9665 365 79734323
Water intoxication 148.85 15.02 31 9669 743 79733945
Hypernatraemia 132.84 15.02 54 9646 14397 79720291
Diabetes insipidus 126.31 15.02 40 9660 5197 79729491
Seizure 125.94 15.02 134 9566 188700 79545988
Osmotic demyelination syndrome 107.91 15.02 27 9673 1486 79733202
Hyponatraemic seizure 99.63 15.02 21 9679 534 79734154
Recalled product administered 96.13 15.02 22 9678 825 79733863
Renal salt-wasting syndrome 94.30 15.02 21 9679 695 79733993
Pharyngeal haemorrhage 81.59 15.02 21 9679 1295 79733393
Germ cell cancer 69.35 15.02 13 9687 177 79734511
Labelled drug-disease interaction medication error 68.23 15.02 14 9686 311 79734377
Polyuria 58.65 15.02 31 9669 14983 79719705
Blood sodium decreased 55.77 15.02 40 9660 33215 79701473
Poor quality product administered 52.86 15.02 19 9681 3626 79731062
Brain injury 51.38 15.02 26 9674 11491 79723197
Hypopituitarism 50.35 15.02 18 9682 3381 79731307
Neoplasm recurrence 50.17 15.02 19 9681 4195 79730493
Product prescribing error 45.24 15.02 40 9660 44773 79689915
Adrenocortical insufficiency acute 44.65 15.02 16 9684 3027 79731661
Blood sodium increased 44.32 15.02 18 9682 4780 79729908
Tonsillar disorder 40.43 15.02 12 9688 1254 79733434
Inappropriate antidiuretic hormone secretion 38.15 15.02 29 9671 26284 79708404
Apnoeic attack 38.13 15.02 10 9690 664 79734024
Chorioretinopathy 37.58 15.02 13 9687 2218 79732470
Head titubation 34.85 15.02 10 9690 928 79733760
Insulin-like growth factor decreased 34.64 15.02 9 9691 576 79734112
Oligohydramnios 32.20 15.02 13 9687 3399 79731289
Electrolyte imbalance 32.03 15.02 28 9672 30853 79703835
Flushing 31.73 15.02 46 9654 88222 79646466
Oesophageal disorder 31.66 15.02 12 9688 2655 79732033
Urine osmolarity decreased 31.04 15.02 6 9694 97 79734591
Nephrogenic diabetes insipidus 30.48 15.02 11 9689 2123 79732565
Epiphysiolysis 30.03 15.02 6 9694 116 79734572
Duplicate therapy error 29.67 15.02 7 9693 300 79734388
Hyperadrenocorticism 28.62 15.02 7 9693 350 79734338
Insulin-like growth factor increased 27.98 15.02 10 9690 1876 79732812
Polydipsia 26.82 15.02 14 9686 6591 79728097
Abortion induced 25.86 15.02 14 9686 7095 79727593
Contraindicated product prescribed 25.06 15.02 9 9691 1712 79732976
Urine osmolarity increased 24.67 15.02 6 9694 293 79734395
Hypothalamo-pituitary disorder 24.22 15.02 8 9692 1186 79733502
Thoracotomy 24.12 15.02 5 9695 117 79734571
Epistaxis 23.79 15.02 46 9654 111469 79623219
Hypoosmolar state 23.79 15.02 6 9694 341 79734347
Cogwheel rigidity 23.20 15.02 10 9690 3078 79731610
Rebound effect 22.91 15.02 13 9687 7213 79727475
Therapeutic response decreased 22.81 15.02 34 9666 66819 79667869
Reaction to excipient 21.98 15.02 8 9692 1581 79733107
CNS germinoma 21.97 15.02 3 9697 3 79734685
Urine sodium increased 21.53 15.02 5 9695 200 79734488
Headache 21.24 15.02 144 9556 653628 79081060
Hepatitis toxic 21.16 15.02 11 9689 5136 79729552
Joint swelling 20.41 15.02 5 9695 288641 79446047
Cutaneous lupus erythematosus 20.21 15.02 9 9691 2994 79731694
Urine output decreased 20.03 15.02 17 9683 18005 79716683
Drug intolerance 19.83 15.02 4 9696 264115 79470573
Gastrointestinal infection 19.70 15.02 14 9686 11447 79723241
Drug interaction 19.64 15.02 101 9599 415082 79319606
Drug hypersensitivity 19.60 15.02 6 9694 298910 79435778
Product use in unapproved indication 18.80 15.02 70 9630 250289 79484399
Pituitary tumour benign 18.24 15.02 8 9692 2568 79732120
Urinary retention 18.18 15.02 28 9672 56602 79678086
Metastases to pituitary gland 17.94 15.02 3 9697 20 79734668
Akathisia 17.88 15.02 14 9686 13245 79721443
Nasal discomfort 17.75 15.02 10 9690 5473 79729215
Toxic neuropathy 17.63 15.02 6 9694 974 79733714
Generalised tonic-clonic seizure 17.42 15.02 24 9676 43886 79690802
Hyperthermia malignant 17.28 15.02 8 9692 2909 79731779
Pollakiuria 17.28 15.02 22 9678 37295 79697393
Extrapyramidal disorder 16.68 15.02 17 9683 22662 79712026
Foetal growth restriction 16.37 15.02 7 9693 2112 79732576
Arthralgia 16.17 15.02 28 9672 571775 79162913
Pain 16.06 15.02 39 9661 703763 79030925
Rheumatoid arthritis 15.98 15.02 3 9697 208467 79526221
Urine output increased 15.95 15.02 7 9693 2249 79732439
Dihydrotestosterone increased 15.93 15.02 3 9697 42 79734646
Astrocytoma 15.86 15.02 4 9696 227 79734461
Off label use 15.80 15.02 174 9526 907041 78827647
Anticholinergic syndrome 15.66 15.02 8 9692 3603 79731085
Thirst 15.63 15.02 15 9685 18604 79716084
Blood growth hormone increased 15.20 15.02 5 9695 731 79733957
Astrocytoma, low grade 15.17 15.02 3 9697 55 79734633
Brain oedema 15.16 15.02 17 9683 25246 79709442

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01BA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA CS M0022562 Vasopressins
CHEBI has role CHEBI:33295 diagnostic aid
CHEBI has role CHEBI:35846 renal agents
CHEBI has role CHEBI:59727 arginine vasopressin receptor agonist
MeSH PA D050034 Antidiuretic Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D045283 Natriuretic Agents
FDA EPC N0000175905 Vasopressin Analog
FDA PE N0000175914 Increased Coagulation Factor VIII Activity
FDA PE N0000175915 Increased Coagulation Factor VIII Concentration
FDA EPC N0000175916 Factor VIII Activator

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
Polyuria indication 28442001
von Willebrand disorder indication 128105004 DOID:12531
Partial Central Diabetes Insipidus indication
Uremic Bleeding Tendency off-label use
Psychogenic polydipsia contraindication 15945005
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Upper respiratory infection contraindication 54150009
Allergic rhinitis contraindication 61582004
Nasal discharge contraindication 64531003
Nasal congestion contraindication 68235000
Water intoxication syndrome contraindication 71785001
Hyponatremia contraindication 89627008
Cystic fibrosis contraindication 190905008 DOID:1485
Impaired renal function disorder contraindication 197663003
Finding of excessive fluid intake contraindication 267026004
Hereditary von Willebrand disease type 2B contraindication 359717002
Disorder of coronary artery contraindication 414024009
Severe Allergic Rhinitis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.27 acidic
pKa3 12.64 acidic
pKa4 12.94 acidic
pKa5 13.39 acidic
pKa6 13.43 acidic
pKa7 13.8 acidic
pKa8 10.75 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9220747 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9504647 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9919025 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9220747 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9504647 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9919025 May 7, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 8802624 Dec. 29, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 8802624 Dec. 29, 2023 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 7560429 Feb. 2, 2024 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 7560429 Feb. 2, 2024 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 11020448 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 10137167 May 21, 2029 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0277MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG NOCDURNA FERRING PHARMS INC N022517 June 21, 2018 RX TABLET SUBLINGUAL 9974826 April 13, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.00083MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 11419914 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
0.00166MG/SPRAY NOCTIVA ACERUS PHARMS N201656 March 3, 2017 DISCN SPRAY, METERED NASAL 11419914 June 15, 2030 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vasopressin V2 receptor GPCR AGONIST Ki 8.30 CHEMBL SCIENTIFIC LITERATURE
Vasopressin V1b receptor GPCR Ki 9.43 CHEMBL
Oxytocin receptor GPCR AGONIST Ki 7.60 IUPHAR
Vasopressin V1a receptor GPCR Ki 8.42 CHEMBL
Oxytocin receptor GPCR Ki 9.01 CHEMBL
Vasopressin V1a receptor GPCR Ki 7.97 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.70 CHEMBL
Vasopressin V2 receptor GPCR Ki 9.10 CHEMBL

External reference:

IDSource
4019709 VUID
N0000170340 NUI
D00291 KEGG_DRUG
62357-86-2 SECONDARY_CAS_RN
203658 RXNORM
4018750 VANDF
4019709 VANDF
C0011701 UMLSCUI
CHEBI:4450 CHEBI
CHEMBL376685 ChEMBL_ID
CHEMBL1429 ChEMBL_ID
CHEMBL1200556 ChEMBL_ID
DB00035 DRUGBANK_ID
2182 IUPHAR_LIGAND_ID
3799 INN_ID
ENR1LLB0FP UNII
5311065 PUBCHEM_CID
1069 MMSL
4548 MMSL
48087 MMSL
772 MMSL
d00583 MMSL
002125 NDDF
004784 NDDF
126189002 SNOMEDCT_US
126190006 SNOMEDCT_US
73454001 SNOMEDCT_US
D003894 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Stimate HUMAN PRESCRIPTION DRUG LABEL 1 0053-6871 SPRAY, METERED 1.50 mg NASAL NDA 23 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0517-4310 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2464 TABLET 0.10 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2464 TABLET 0.10 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2464 TABLET 0.10 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2465 TABLET 0.20 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2465 TABLET 0.20 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2465 TABLET 0.20 mg ORAL ANDA 19 sections
Desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 0703-5051 INJECTION 4 ug INTRAVENOUS ANDA 21 sections
Desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 0703-5054 INJECTION 4 ug INTRAVENOUS ANDA 21 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-169 TABLET 0.10 mg ORAL ANDA 11 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 10702-170 TABLET 0.20 mg ORAL ANDA 11 sections
Desmopressin Acetate Human Prescription Drug Label 1 16714-015 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16714-883 TABLET 0.10 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16714-884 TABLET 0.20 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-489 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-489 TABLET 0.10 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-490 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 23155-490 TABLET 0.20 mg ORAL ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 24208-342 SOLUTION 0.10 mg NASAL ANDA 27 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-460 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 21 sections
desmopressin acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-461 INJECTION, SOLUTION 40 ug INTRAVENOUS ANDA 20 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-053 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 25 sections
DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 43598-931 INJECTION 4 ug SUBCUTANEOUS ANDA 13 sections
Desmopressin Acetate Human Prescription Drug Label 1 47335-788 SOLUTION 0.10 mg NASAL ANDA 24 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 50268-220 TABLET 0.10 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 50268-221 TABLET 0.20 mg ORAL ANDA 19 sections
Desmopressin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51655-461 TABLET 0.20 mg ORAL ANDA 11 sections
NOCDURNA HUMAN PRESCRIPTION DRUG LABEL 1 54436-325 TABLET 27.70 ug SUBLINGUAL NDA 29 sections
NOCDURNA HUMAN PRESCRIPTION DRUG LABEL 1 54436-350 TABLET 55.30 ug SUBLINGUAL NDA 29 sections